Real-world, 52-week prospective study to capture the reasons for switch to triple combination therapy, assess the clinical and patient reported outcomes in adults with moderate to severe Chronic Obstructive Pulmonary Disease (COPD) treated with Trixeo Aerosphere™ in routine care settings in Greece - TRIAENA

Study identifier:D5980R00082

ClinicalTrials.gov identifier:NCT05915182

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

A real-world, multicenter, 52-week prospective cohort study to capture the reasons for switch to triple combination therapy and to assess the clinical and patient reported outcomes in adults with moderate to severe COPD treated with Trixeo Aerosphere™ in routine care settings in Greece.

Medical condition

Pulmonary Disease, Chronic Obstructive (COPD)

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

200

Study type

Observational

Age

40 Years - 80 Years

Date

Study Start Date: 21 Jul 2023
Estimated Primary Completion Date: 31 Oct 2025
Estimated Study Completion Date: 31 Oct 2025

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Aug 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria